Work

A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.4_suppl.500

Authors: Richard D. Kim, Nilofer Saba Azad, Michael Morse, Benjamin R. Tan, Elizabeth Poplin, Melony A. Beatson, Sharon Mavroukakis, Philip M. Arlen, Muhammad Shaalan Beg

Institutions: Moffitt Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Duke Medical Center, Washington University in St. Louis, Rutgers Cancer Institute, The University of Texas Southwestern Medical Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591494309

Cites:

Cited by:

Related to: 10